Psychiatr. pro Praxi, 2005; 5: 241-245
NEW SYNTHETIC DRUGS
The drug scene is developing similarly as any other scene. According to this fact new problems that have to be solved are arising. One of the most prominent problems of the 21st century is increasing frequency of the use of new synthetic drugs. This phenomenon is closely linked to the widespread use of designer drug ecstasy (3,4-methylendioxymethamphetamine, MDMA). New synthetic drugs are most often associated to the population of ecstasy users, often distributed as to be the ecstasy itself or something similar to it. Phenylethylamine, tryptamine and piperazine derivatives most likely belong to this category. In general, these are drugs acting predominantly via monoaminergic systems of the brain, having entactogenic, hallucinogenic and stimulant properties. Whenever these substances in some cases could be highly toxic, there is substantial lack of valid and accessible information about them.
Keywords: Key words: exstasy, MDMA, phenylethylamines, tryptamines, piperazines, new synthetic drugs.
Published: February 1, 2006 Show citation
References
- Balmelli C, Kupferschmidt H, Rentsch K, Schneemann M. [Fatal brain edema after ingestion of ecstasy and benzylpiperazine]. Dtsch.Med.Wochenschr. 2001; 126/28-29: 809-811.
Go to original source... 
Go to PubMed... - Baumann MH, Clark RD, Budzynski AG, Partilla JS, Blough BE, Rothman RB. N-substituted piperazines abused by humans mimic the molecular mechanism of 3,4-methylenedioxymethamphetamine (MDMA, or, Ecstasy). Neuropsychopharmacology 2005; 30/3: 550-560. Go to original source... Go to PubMed...
- Berger M. Trifluoromethylphenylpiperazine (TFMPP): An Entheogenic Entactogen. Erowid.org 2003: http://www.erowid.org/chemicals/piperazines/tfmpp_article1.shtml.
- BilZ0r Neuropharmacology of BZP. Erowid.org 2003: http://www.erowid.org/chemicals/bzp/bzp_article1.shtml.
- Carter N, Rutty GN, Milroy CM, Forrest AR. Deaths associated with MBDB misuse. Int.J.Legal Med. 2000; 113/3: 168-170. Go to original source... Go to PubMed...
- Collection and toxicological analysis in the framework of SINTES. 4-7-2003.
- Csémy L, Sovinová M, Komárek J. Drogy a taneční scéna. Státní zdravotní ústav 2000.
- de Boer D, Bosman IJ, Hidvegi E, Manzoni C, Benko AA, dos Reys LJ, Maes RA. Piperazine-like compounds: a new group of designer drugs-of-abuse on the European market. Forensic Sci.Int. 2001; 121/1-2: 47-56. Go to original source... Go to PubMed...
- EMCDDA information sheet - BZP (A2). European monitoring Centre for Drugs and Drug Addiction (EMCDDA) 2005.
- Feuchtl A, Bagli M, Stephan R, Frahnert C, Kolsch H, Kuhn KU, Rao ML. Pharmacokinetics of m-chlorophenylpiperazine after intravenous and oral administration in healthy male volunteers: implication for the pharmacodynamic profile. Pharmacopsychiatry 2004; 37/4: 180-188. Go to original source... Go to PubMed...
- Fišerová M, Páleníček T. MDMA (3,4-metylendioxymetamfetamin), ,Extáze". Adiktologie 2001; 1/2: 48-59.
- Glennon RA, Slusher RM, Lyon RA, Titeler M, McKenney JD. 5-HT1 and 5-HT2 binding characteristics of some quipazine analogues. J. Med. Chem. 1986; 29/11: 2375-2380. Go to original source... Go to PubMed...
- Gobbi M, Moia M, Pirona L, Ceglia I, Reyes-Parada M, Scorza C, Mennini T. p-Methylthioamphetamine and 1-(m-chlorophenyl)piperazine, two non-neurotoxic 5-HT releasers in vivo, differ from neurotoxic amphetamine derivatives in their mode of action at 5-HT nerve endings in vitro. J.Neurochem. 2002; 82/6: 1435-1443. Go to original source... Go to PubMed...
- Green AL, El Hait MA. A new approach to the assessment of the potency of reversible monoamine oxidase inhibitors in vivo, and its application to (+)-amphetamine, p-methoxyamphetamine and harmaline. Biochem.Pharmacol. 1980; 29/20: 2781-2789. Go to original source... Go to PubMed...
- Green AL, El Hait MA. p-Methoxyamphetamine, a potent reversible inhibitor of type-A monoamine oxidase in vitro and in vivo. J.Pharm.Pharmacol. 1980; 32/4: 262-266. Go to original source... Go to PubMed...
- Huang X, Marona-Lewicka D, Nichols DE. p-methylthioamphetamine is a potent new non-neurotoxic serotonin-releasing agent. Eur.J.Pharmacol. 1992; 229/1: 31-38. Go to original source... Go to PubMed...
- Kubů T, Škařupová K, Csémy L. Kontext rekreační konzumace drog v roce 2003 na území ČR: vybrané výsledky studie Tanec a drogy 2000 a 2003. Adiktologie 2005; 5/1: 61-75.
- Leuner H, Baer G. Two new short-acting hallucinogens of the psilocybin group. Neuropsychopharmacology 1965; 4 471-474.
- Li Q, Murakami I, Stall S, Levy AD, Brownfield MS, Nichols DE, Van de Kar LD. Neuroendocrine pharmacology of three serotonin releasers: 1-(1,3-benzodioxol-5-yl)2-(methylamino)butane (MBDB), 5-methoxy-6-methyl-2-aminoindan (MMAi) and p-methylthioamphetamine (MTA). J.Pharmacol.Exp.Ther. 1996; 279/3: 1261-1267. Go to PubMed...
- May JA, Chen HH, Rusinko A, Lynch VM, Sharif NA, McLaughlin MA. A novel and selective 5-HT2 receptor agonist with ocular hypotensive activity: (S)-(+)-1-(2-aminopropyl)-8,9-dihydropyrano[3,2-e]indole. J. Med. Chem. 2003; 46/19: 4188-4195. Go to original source... Go to PubMed...
- McKenney JD, Glennon RA. TFMPP may produce its stimulus effects via a 5-HT1B mechanism. Pharmacol.Biochem.Behav. 1986; 24/1: 43-47. Go to original source... Go to PubMed...
- Nichols DE. Differences between the mechanism of action of MDMA, MBDB, and the classic hallucinogens. Identification of a new therapeutic class: entactogens. J.Psychoactive Drugs 1986; 18/4: 305-313. Go to original source... Go to PubMed...
- Páleníček T, Kubů P, Mravčík V. Nové syntetické drogy - charakteristika a hlavní rizika. Úřad vlády České republiky, Nábřeží E. Beneše 4, 118 01 2004.
- Páleníček T, Šustková M. Extáze - tajemný tanec. Psychiatrie 2003; 7/2: 101-109.
- Report on the risk assessment of 2C-I, 2C-T-2 and 2C-T-7 in the framework of the joint action on new synthetic drugs. European monitoring Centre for Drugs and Drug Addiction (EMCDDA) 2004.
- Report on the risk assessment of 4-MTA in the framework of the joint action on new synthetic drugs. European monitoring Centre for Drugs and Drug Addiction (EMCDDA) 1999.
- Report on the Risk Assessment of MBDB in the Framework of the Joint Action on New Synthetic Drugs. European monitoring Centre for Drugs and Drug Addiction (EMCDDA) 1999.
- Report on the risk assessment of PMMA in the framework of the joint action on new synthetic drugs. European monitoring Centre for Drugs and Drug Addiction (EMCDDA) 2003.
- Report on the risk assessment of TMA-2 in the framework of the joint action on new synthetic drugs. European monitoring Centre for Drugs and Drug Addiction (EMCDDA) 2004.
- Rotzinger S, Fang J, Baker GB. Trazodone is metabolized to m-chlorophenylpiperazine by CYP3A4 from human sources. Drug Metab Dispos. 1998; 26/6: 572-575.
- Rotzinger S, Fang J, Coutts RT, Baker GB. Human CYP2D6 and metabolism of m-chlorophenylpiperazine. Biol.Psychiatry 1998; 44/11: 1185-1191. Go to original source... Go to PubMed...
- Shulgin A, Shulgin A. PIHKAL: A Chemical Love Story. Transform Press 1991.
- Shulgin A, Shulgin A. TIHKAL: The Continuation. Transform press 1997.
- Schechter M.D. Use of TFMPP stimulus properties as a model of 5-HT1B receptor activation. Pharmacol.Biochem.Behav. 1988; 31/1: 53-57. Go to original source... Go to PubMed...
- Summary by substance according to the EWS Progress and Yearly Reports - 2004. 2005.
- Tohyama Y, Yamane F, Fikre MM, Blier P, Diksic M. Effects of serotine receptors agonists, TFMPP and CGS12066B, on regional serotonin synthesis in the rat brain: an autoradiographic study. J.Neurochem. 2002; 80/5: 788-798. Go to original source... Go to PubMed...
- Tossmann P, Boldt S, Tensil MD. The use of drugs within the techno party scene in European metropolitan cities. Eur.Addict.Res. 2001; 7/1: 2-23. Go to original source... Go to PubMed...
- Winter JC, Filipink RA, Timineri D, Helsley SE, Rabin RA. The paradox of 5-methoxy-N,N-dimethyltryptamine: an indoleamine hallucinogen that induces stimulus control via 5-HT1A receptors. Pharmacol.Biochem.Behav. 2000; 65/1: 75-82. Go to original source... Go to PubMed...